New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT07128303
Summary
This is the first study in people to test a new drug called GS-5319. The main goal is to find a safe dose and understand the side effects in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to work specifically in tumors missing a gene called MTAP.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
START Madrid - FJD - Hospital Fundación Jiménez Díaz - Phase I Clinical Trials Unit
RECRUITINGMadrid, 28040, Spain
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Vall d'Hebron Institute of Oncology (VHIO)
RECRUITINGBarcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.